The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
Abstract
Swift elimination of undesirable cells is an important feature in tumour suppression and immunity. The tumour suppressor p53 and interferon-alpha and -beta (IFN-alpha/beta) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship. Here we show that transcription of the p53 gene is induced by IFN-alpha/beta, accompanied by an increase in p53 protein level. IFN-alpha/beta signalling itself does not activate p53; rather, it contributes to boosting p53 responses to stress signals. We show examples in which p53 gene induction by IFN-alpha/beta contributes to tumour suppression. Furthermore, we show that p53 is activated in virally infected cells to evoke an apoptotic response and that p53 is critical for antiviral defence of the host. Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In response to senesce-inducing stimuli, senescent cells produce, in a cGAS-dependent manner, type I interferons that have pro-senescence and anti-proliferative activities.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
In the citing paper
“Indeed, β-interferons increase ROS production, leading to DNA damage and p53 activation [273,274].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“2a ); ISRE is activated by the IFN-activated transcription factor ISGF3, a heterotrimeric complex consisting of a signal transducer and activator of transcription factor 1 (Stat1), Stat2 and interferon regulatory factor 9 (IRF-9”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Previous studies have shown that p53 -deficient mice show no sign of abnormality in T and B cells, and that they can mount adaptive immune responses normall”
ResultMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024 · cited 1×
“Persistent infection with oncogenic HPV types represents a major risk factor for the development of cervical cancer, in which E6 is known to have a critical role (together with another oncoprotein, E7 (ref”
BackgroundDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 1×
“We infer that, similar to DNA damage, ATM activation is caused by changes in the chromatin structure in virus-infected cell”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“We also examined the effect of IFN-β on the DNA damage-induced apoptotic response of MEFs expressing the adenovirus E1A oncoprotein, as it is well known that this response is p53-dependent and critical for tumour suppressio”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Self-citationDNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 1×
“Furthermore, the same observation—that is, phosphorylation of Ser 15 of human p53 (ref”
BackgroundThe HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
Scheffner, M., Huibregtse, J. M., Vierstra, R. D., & Howley, P. M. (1993) · Cell · doi:10.1016/0092-8674(93)90384-3 · Cited by 2,054 · cited 1×
“One of the best-known examples is the E6 gene of the human papilloma viruses (HPV), the product of which targets p53 by inducing its degradation by the ubiquitin proteolytic pathwa”
BackgroundActivation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825 · cited 1×
“On the other hand, IFN-α/β, both of which are essential cytokines for antiviral immunity, are sometimes referred to as ‘negative growth factors’, and manifest anti-oncogenic activitie”
BackgroundEnhanced Phosphorylation of p53 by ATM in Response to DNA Damage
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797
A Matter of Life and Cell Death
Evan, G., & Littlewood, T. (1998) · Science · doi:10.1126/science.281.5381.1317 · Cited by 1,523
Viruses and interferon: a fight for supremacy
Katze, M. G., He, Y., & Gale, M. (2002) · Nature Reviews Immunology · doi:10.1038/nri888 · Cited by 1,419
Sato, M., Suemori, H., Hata, N., Asagiri, M., Ogasawara, K., Nakao, K., Nakaya, T., Katsuki, M., Noguchi, S., Tanaka, N., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00053-4 · Cited by 1,339
Self-citationDisruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044 · cited 1×
“5-Fluorouracil (5-FU) is one agent whose efficacy closely correlates with the p53 status of cancer cell”
BackgroundInterferons: cell signalling, immune modulation, antiviral response and virus countermeasures
Goodbourn, S., Didcock, L., & Randall, R. E. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-10-2341 · Cited by 977
Cytokine therapeutics: lessons from interferonalpha.
Gutterman, J. U. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.4.1198 · Cited by 703 · cited 1×
“In fact, IFN-α/β are used for the treatment of some forms of human cancer but the molecular basis for the treatment is poorly understoo”
MethodInterferons α and β as Immune Regulators—A New Look
Biron, C. A. (2001) · Immunity · doi:10.1016/s1074-7613(01)00154-6 · Cited by 667
Sherr, C. J., & Weber, J. D. (2000) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)00038-6 · Cited by 654 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodTanaka, N., Ishihara, M., Kitagawa, M., Harada, H., Kimura, T., Matsuyama, T., Lamphier, M. S., Aizawa, S., Mak, T. W., & Taniguchi, T. (1994) · Cell · doi:10.1016/0092-8674(94)90132-5 · Cited by 491 · cited 1×
“Retroviral expression The expression of activated Ha-Ras was mediated by retroviral gene transfer, wherein the pGDV12ras was used as described previousl”
MethodSelf-citationPfeffer, L. M., Dinarello, C. A., Herberman, R. B., Williams, B. R. G., Borden, E. C., Bordens, R. W., Walter, M. R., Nagabhushan, T. L., Trotta, P. P., & Pestka, S. (1998) · PubMed · Cited by 480
Genetic determinants of p53-induced apoptosis and growth arrest.
Polyak, K., Waldman, T., He, T. C., Kinzler, K. W., & Vogelstein, B. (1996) · Genes & Development · doi:10.1101/gad.10.15.1945 · Cited by 459 · cited 1×
“Although the mechanism of this differential activation of p53-inducible genes is currently unknown, it is interesting that p21 WAF1/Cip1 , the induction of which acts in favour of cell survival (ref”
BackgroundThe virus battles: IFN induction of the antiviral state and mechanisms of viral evasion
Levy, D. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00027-7 · Cited by 428
Interferons and other regulatory cytokines
Demaeyer, E. M., & Maeyer‐Guignard, J. D. (1988) · Medical Entomology and Zoology · Cited by 419
Wadler, S., & Schwartz, E. L. (1990) · PubMed · Cited by 342
Enhanced proliferative potential in culture of cells from p53-deficient mice.
Tsukada, T., Tomooka, Y., Takai, S., Ueda, Y., Nishikawa, S.-I., Yagi, T., Tokunaga, T., Takeda, N., Suda, Y., & Abe, S. (1993) · PubMed · Cited by 341
Cross Talk Between Interferon-γ and -α/β Signaling Components in Caveolar Membrane Domains
Takaoka, A., Mitani, Y., Suemori, H., Sato, M., Yokochi, T., Noguchi, S., Tanaka, N., & Taniguchi, T. (2000) · Science · doi:10.1126/science.288.5475.2357 · Cited by 319
Self-citationInterferons and other regulatory cytokines
Meager, A. (1989) · Journal of Immunological Methods · doi:10.1016/0022-1759(89)90301-3 · Cited by 304
Cell-cycle control and its watchman
Jacks, T., & Weinberg, R. A. (1996) · Nature · doi:10.1038/381643a0 · Cited by 274
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines
Hsu, I. C., Tokiwa, T., Bennett, W., Metcalf, R. A., Welsh, J. A., Sun, T., & Harris, C. C. (1993) · Carcinogenesis · doi:10.1093/carcin/14.5.987 · Cited by 241 · cited 1×
“The p53 induction by IFN-β was also observed in two human hepatic cancer cell lines, HepG2 and HLE, p53 function being abrogated in the latter cells by a mutation in the DNA-binding domai”
BackgroundVeldman, T., Horikawa, I., Barrett, J. C., & Schlegel, R. (2001) · Journal of Virology · doi:10.1128/jvi.75.9.4467-4472.2001 · Cited by 237 · cited 1×
“On the other hand, the expression of the mRNAs for E6 and mTERT, a telomerase subunit known to be E6-inducibl”
BackgroundKimura, T., Kadokawa, Y., Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Tarutani, M., Sok‐Pin Tan, R., Takasugi, T., Matsuyama, T., et al. (1996) · Genes to Cells · doi:10.1046/j.1365-2443.1996.08008.x · Cited by 234
Self-citationFujita, T., Ohno, S., Yasumitsu, H., & Taniguchi, T. (1985) · Cell · doi:10.1016/s0092-8674(85)80022-2 · Cited by 208
Self-citationRelationship of p53 to the control of apoptotic cell death.
Oren, M. (1994) · PubMed · Cited by 164
ISGF3γ p48, a specificity switch for interferon activated transcription factors
Bluyssen, H. A. R. (1996) · Cytokine & Growth Factor Reviews · doi:10.1016/1359-6101(96)00005-6 · Cited by 158
Functional p53 protein in human papillomavirus-positive cancer cells.
Butz, K., Shahabeddin, L., Geisen, C., Spitkovsky, D., Ullmann, A., & Hoppe‐Seyler, F. (1995) · PubMed · Cited by 146
Control of interferon signaling in human papillomavirus infection
Koromilas, A. E. (2001) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(00)00023-x · Cited by 112 · cited 1×
“There are numerous reports on the usefulness of IFN-α/β for the treatment of some types of human cancer, including HPV-associated cervical cancer and hepatic cance”
BackgroundEndogenous type I interferons as a defense against tumors
Gresser, I., & Belardelli, F. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00035-1 · Cited by 105 · cited 1×
“On the other hand, IFN-α/β, both of which are essential cytokines for antiviral immunity, are sometimes referred to as ‘negative growth factors’, and manifest anti-oncogenic activitie”
BackgroundWestphal, C. H., Schmaltz, C., Rowan, S., Elson, A., Fisher, D. E., & Leder, P. (1997) · PubMed · Cited by 81
Haque, S. J., & Williams, B. R. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)32200-7 · Cited by 77
Protein-binding elements in the promoter region of the mouse p53 gene.
Ginsberg, D., Oren, M., Yaniv, M., & Piette, J. (1990) · PubMed · Cited by 73
Mendonca, M. S., Howard, K. L., Farrington, D. L., Desmond, L. A., Temples, T., Mayhugh, B. M., Pink, J. J., & Boothman, D. A. (1999) · PubMed · Cited by 45
p53 and tumour viruses: Catching the guardian off-guard
Neil, J. C., Cameron, E. R., & Baxter, E. W. (1997) · Trends in Microbiology · doi:10.1016/s0966-842x(96)10083-4 · Cited by 33
Miyamoto, A., Umeshita, K., Sakon, M., Nagano, H., Eguchi, H., Kishimoto, S., Dono, K., Nakamori, S., Gotoh, M., & Monden, M. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02289.x · Cited by 32
Interferons and the tumor cell
Strander, H. A., & Einhorn, S. (1996) · Biotherapy · doi:10.1007/bf01877207 · Cited by 27 · cited 1×
“In fact, IFN-α/β are used for the treatment of some forms of human cancer but the molecular basis for the treatment is poorly understoo”
MethodCellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Research works printed but not linked: 1
- Vilcek, J. & Sen, G. S. in Fields Virology 3rd edn (eds Fields, D. M., Knipe, P. M. & Howley, P. M.) 375–399 (Lippincott-Raven, Philadelphia, 1996)
Cited by
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
“Type I IFNs are critical for antiviral and antitumour responses in healthy cells not only because they promote immune responses to clear the virus, but also because they reduce cellular proliferation and activate the proapoptotic protein p53 (REF. 62 ).”
BackgroundCytokines in cancer pathogenesis and cancer therapy
Dranoff, G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1252 · Cited by 1,573
Metadata
- Authors
- Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., & Taniguchi, T.
- Affiliations
- The University of Tokyo (JP)
- University of Vienna (AT)
- Sapporo Medical University (JP)
- Corresponding author
- Taniguchi, Tadatsugu
- ORCID
- Venue
- Nature
- Published
- 2003-07
- Volume
- 424
- Issue
- 6948
- Pages
- 516-523
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2119885778
- Cited by
- 847
- References
- 51
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 20 · 2023: 25 · 2022: 22 · 2021: 32 · 2020: 41 · 2019: 40 · 2018: 21 · 2017: 38 · 2016: 50 · 2015: 44 · 2014: 40 · 2013: 46 · 2012: 38
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Boehringer Ingelheim Japan
- Senri Life Science Foundation
- Kanae Foundation for the Promotion of Medical Science
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, type I interferon, interferon signaling, tumor suppression, antiviral defense, apoptosis, viral infection, cancer therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Humans, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Vesicular stomatitis Indiana virus, Signal Transduction, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Interferon-alpha, Interferon-beta, Apoptosis, Response Elements, Interferon-Stimulated Gene Factor 3, Interferon-Stimulated Gene Factor 3, gamma Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.